search
Back to results

PFO Occlusion and Atrial Fibrillation

Primary Purpose

Atrial Fibrillation New Onset, Embolic Stroke of Undetermined Source, Patent Foramen Ovale

Status
Unknown status
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
PFO closure
Sponsored by
University Hospital, Saarland
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrial Fibrillation New Onset

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Previous embolic stroke with undetermined source with…
  • palpitations with clinical indication for an electrophysiological study (control group)
  • PFO and clinical indication for interventional PFO closure according to current guidelines (intervention group)
  • Sinus rhythm at time of inclusion with no history of AF
  • Planned EP study due to reported palpitations or documented burden of non-sustained atrial arrythymias (>100 atrial ectopic beats /24 hours, atrial tachycardia)
  • Written informed consent

Exclusion Criteria:

  • previously documented AF
  • indication for therapeutic anticoagulation
  • uncontrolled diabetes mellitus
  • acute coronary syndrom or acute cardiac decompensation within the last 6 months before enrollment
  • enrolled in another study
  • BMI > 40 kg/m²
  • patients who are pregnant of breastfeeding life expectancy < 6 months
  • relevant peripheral artery disease
  • substance abuse

Sites / Locations

  • Universitätsklinikum des SaarlandesRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

PFO closure

NO PFO

Arm Description

Patients with embolic stroke of undetermined source (ESUS) with patent foramen ovale (PFO) eligible for interventional PFO occlusion receiving a structured electrophysiological study due to palpitations before the PFO closure. Extensive cardiac monitoring.

Patients with embolic stroke of undetermined source (ESUS) with NO patent foramen ovale (PFO) receiving a structured electrophysiological study due to palpitations. Extensive cardiac monitoring.

Outcomes

Primary Outcome Measures

Change in baseline heart rhythm, e.g. new-onset atrial fibrillation
Rate of detection of new-onset atrial fibrillation with Holter and loop recorder monitoring after electrophysiological study

Secondary Outcome Measures

Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study
Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation
Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study
Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation
Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study
Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation
Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study
Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation
Change in left atrial morphology (LA volume index) following PFO closure
Assessment of the change in left atrial morphology and function (LA volume index) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA volume index, physiologocal parameter
Change in left atrial function (LA strain) following PFO closure
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Change in new-onset AF following PFO closure
Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG
Change in left atrial morphology (LA volume index) following PFO closure
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Change in left atrial function (LA strain) following PFO closure
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Change in new-onset AF following PFO closure
Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG
Change in left atrial morphology (LA volume index) following PFO closure
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Change in left atrial function (LA strain) following PFO closure
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Change in new-onset AF following PFO closure
Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG
Change in left atrial morphology (LA volume index) following PFO closure
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Change in left atrial function (LA strain) following PFO closure
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Change in new-onset AF following PFO closure
Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG

Full Information

First Posted
September 13, 2020
Last Updated
May 19, 2021
Sponsor
University Hospital, Saarland
search

1. Study Identification

Unique Protocol Identification Number
NCT04898361
Brief Title
PFO Occlusion and Atrial Fibrillation
Official Title
Electrophysiological and Echocardiographic PREDICTors of Atrial Fibrillation Following Interventional Closure of Patent Foramen Ovale in Cryptogenic Stroke: PREDICT-AF-PFO
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Unknown status
Study Start Date
January 15, 2020 (Actual)
Primary Completion Date
June 2021 (Anticipated)
Study Completion Date
June 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital, Saarland

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Interventional closure of patent foramen ovale (PFO) associates with reduced risk of stroke recurrence in patients with cryptogenic ischemic stroke as reported in the recent CLOSE and REDUCE trials. The long-term follow-up results of the RESPECT and DEFENSE-PFO trial confirmed these findings. PFO closure is therefore recommended in patient with cryptogenic ischemic stroke and PFO according to the current German interdisciplinary guidelines. It is likely that the number of PFO closure procedures will increase significantly in the near future. However, new onset atrial fibrillation (AF) appears to increase in patients following this procedure. In the REDUCE study, new onset atrial fibrillation was detected in 6.6% patients in the PFO closure group compared with 0.4% in the control group (medical treatment); 59% of these patients were diagnosed within the first two weeks following the procedure and 83% within 45 days, respectively. These results were consistent with the CLOSE study: AF was detected in 4.6% patients in the intervention group vs. 0.9% in the control group. Up until today, markers to identify and quantify the individual risk of AF onset are lacking. Furthermore, under-reporting and under-detection of AF occurrence after PFO closure is likely. This study is designed to to assess the prevalence and and identification of electrophysiological and echocardiographic parameters of new-onset AF.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation New Onset, Embolic Stroke of Undetermined Source, Patent Foramen Ovale

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
PFO closure
Arm Type
Active Comparator
Arm Description
Patients with embolic stroke of undetermined source (ESUS) with patent foramen ovale (PFO) eligible for interventional PFO occlusion receiving a structured electrophysiological study due to palpitations before the PFO closure. Extensive cardiac monitoring.
Arm Title
NO PFO
Arm Type
No Intervention
Arm Description
Patients with embolic stroke of undetermined source (ESUS) with NO patent foramen ovale (PFO) receiving a structured electrophysiological study due to palpitations. Extensive cardiac monitoring.
Intervention Type
Procedure
Intervention Name(s)
PFO closure
Intervention Description
Interventional closure of a patent foramen oval preceded by an electrophysiological study
Primary Outcome Measure Information:
Title
Change in baseline heart rhythm, e.g. new-onset atrial fibrillation
Description
Rate of detection of new-onset atrial fibrillation with Holter and loop recorder monitoring after electrophysiological study
Time Frame
1, 3, 6, 12 months
Secondary Outcome Measure Information:
Title
Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study
Description
Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation
Time Frame
1 month
Title
Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study
Description
Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation
Time Frame
3 months
Title
Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study
Description
Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation
Time Frame
6 months
Title
Relevance of atrial refractory periods and inducibility of atrial arrhythmias during the electrophysiological study
Description
Atrial refractory periods are measured and atrial arrhythmias are induced during the electrophysiological study. Measurement: electrophysiological study, Unit of measure: Rate of patients with induced AF during stimulation
Time Frame
12 months
Title
Change in left atrial morphology (LA volume index) following PFO closure
Description
Assessment of the change in left atrial morphology and function (LA volume index) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA volume index, physiologocal parameter
Time Frame
1 month
Title
Change in left atrial function (LA strain) following PFO closure
Description
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Time Frame
1 month
Title
Change in new-onset AF following PFO closure
Description
Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG
Time Frame
1 month
Title
Change in left atrial morphology (LA volume index) following PFO closure
Description
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Time Frame
3 months
Title
Change in left atrial function (LA strain) following PFO closure
Description
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Time Frame
3 months
Title
Change in new-onset AF following PFO closure
Description
Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG
Time Frame
3 months
Title
Change in left atrial morphology (LA volume index) following PFO closure
Description
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Time Frame
6 months
Title
Change in left atrial function (LA strain) following PFO closure
Description
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Time Frame
6 months
Title
Change in new-onset AF following PFO closure
Description
Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG
Time Frame
6 months
Title
Change in left atrial morphology (LA volume index) following PFO closure
Description
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Time Frame
12 months
Title
Change in left atrial function (LA strain) following PFO closure
Description
Assessment of the change in left atrial function (LA strain) during follow-up. Measurement: echocardiography, Unit of measure: Assessment of LA strain, physiologocal parameter
Time Frame
12 months
Title
Change in new-onset AF following PFO closure
Description
Assessment of new-onset AF during follow-up. Measurement: ECG, Holter ECG
Time Frame
12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Previous embolic stroke with undetermined source with… palpitations with clinical indication for an electrophysiological study (control group) PFO and clinical indication for interventional PFO closure according to current guidelines (intervention group) Sinus rhythm at time of inclusion with no history of AF Planned EP study due to reported palpitations or documented burden of non-sustained atrial arrythymias (>100 atrial ectopic beats /24 hours, atrial tachycardia) Written informed consent Exclusion Criteria: previously documented AF indication for therapeutic anticoagulation uncontrolled diabetes mellitus acute coronary syndrom or acute cardiac decompensation within the last 6 months before enrollment enrolled in another study BMI > 40 kg/m² patients who are pregnant of breastfeeding life expectancy < 6 months relevant peripheral artery disease substance abuse
Facility Information:
Facility Name
Universitätsklinikum des Saarlandes
City
Homburg
State/Province
Saarland
ZIP/Postal Code
66421
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christian Ukena, MD
Phone
004968411615912
Email
christian.ukena@uks.eu
First Name & Middle Initial & Last Name & Degree
Dominic Millenaar, MD
Phone
004968411615912
Email
dominic.millenaar@uks.eu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

PFO Occlusion and Atrial Fibrillation

We'll reach out to this number within 24 hrs